Regulations under the 1998 Medical Schemes Act have been amended to provide for COVID-19 screening, clinically appropriate diagnostic tests, medication, medical management (including hospitalisation and the treatment of complications) and rehabilitation, writes Pam Saxby in a Legalbrief Policy Watch report.
In addition, Schedule 2, 3 and 4 substances prescribed for continuous therapy have been excluded from a requirement in terms of which, under normal circumstances, they may not be dispensed for longer than six months. This arrangement will remain in place for a period “not exceeding 18 months”.